ME00230B - 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni - Google Patents
2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oniInfo
- Publication number
- ME00230B ME00230B MEP-2008-461A MEP46108A ME00230B ME 00230 B ME00230 B ME 00230B ME P46108 A MEP46108 A ME P46108A ME 00230 B ME00230 B ME 00230B
- Authority
- ME
- Montenegro
- Prior art keywords
- pyrimidin
- pyrido
- pyridin
- cyclopentyl
- ylamino
- Prior art date
Links
- 201000010099 disease Diseases 0.000 claims abstract 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- -1 trifluoromethylalkyl Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 229920002554 vinyl polymer Polymers 0.000 claims 6
- 229910020008 S(O) Inorganic materials 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 150000002825 nitriles Chemical class 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- QZDZRDATWGQUSE-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC=CC=3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 QZDZRDATWGQUSE-UHFFFAOYSA-N 0.000 claims 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- RNDSKWSXUGROBX-UHFFFAOYSA-N 6-acetyl-2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 RNDSKWSXUGROBX-UHFFFAOYSA-N 0.000 claims 2
- JPJBKLUESOYNLD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC1=CC=CC=N1 JPJBKLUESOYNLD-UHFFFAOYSA-N 0.000 claims 2
- JQDVILMFUIXCRM-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 JQDVILMFUIXCRM-UHFFFAOYSA-N 0.000 claims 2
- POJKMTSCTDNKEZ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(C)=NC=C2C=C(Br)C(=O)N1C1CCCC1 POJKMTSCTDNKEZ-UHFFFAOYSA-N 0.000 claims 2
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 2
- 108091008648 NR7C Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims 2
- 229960001171 acetohydroxamic acid Drugs 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- KECYKUOBQYTMFK-UHFFFAOYSA-N 2-[(6-acetyl-5-piperazin-1-ylpyridin-2-yl)amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1C(C)=O)=CC=C1N1CCNCC1 KECYKUOBQYTMFK-UHFFFAOYSA-N 0.000 claims 1
- GNOBPPBWGCDWJR-UHFFFAOYSA-N 2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(NCCN)=CC=3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 GNOBPPBWGCDWJR-UHFFFAOYSA-N 0.000 claims 1
- VZEIYMGFCZFVGP-UHFFFAOYSA-N 2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCN)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 VZEIYMGFCZFVGP-UHFFFAOYSA-N 0.000 claims 1
- DGXNULHJVNJWJP-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 DGXNULHJVNJWJP-UHFFFAOYSA-N 0.000 claims 1
- WTZZGELFDNPANA-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 WTZZGELFDNPANA-UHFFFAOYSA-N 0.000 claims 1
- RFJNBZVTUKMOKC-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC(N)C1 RFJNBZVTUKMOKC-UHFFFAOYSA-N 0.000 claims 1
- CIEGNEASRBFQLF-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CC(N)CC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 CIEGNEASRBFQLF-UHFFFAOYSA-N 0.000 claims 1
- QYBHBZQEIJFIID-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 QYBHBZQEIJFIID-UHFFFAOYSA-N 0.000 claims 1
- YXHQPGZZOMKDKV-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCC(N)C1 YXHQPGZZOMKDKV-UHFFFAOYSA-N 0.000 claims 1
- KRWHAQTXQAMXTB-UHFFFAOYSA-N 2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 KRWHAQTXQAMXTB-UHFFFAOYSA-N 0.000 claims 1
- XIWCDJIWKPEYPF-UHFFFAOYSA-N 2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CO)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 XIWCDJIWKPEYPF-UHFFFAOYSA-N 0.000 claims 1
- ONLZGBFWCPBYLE-UHFFFAOYSA-N 2-[[5-(azetidin-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC1 ONLZGBFWCPBYLE-UHFFFAOYSA-N 0.000 claims 1
- PKSPQJGYKMMCFO-UHFFFAOYSA-N 2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C(C)(N)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 PKSPQJGYKMMCFO-UHFFFAOYSA-N 0.000 claims 1
- GLIAQJVFZZCNRM-UHFFFAOYSA-N 2-[[5-[3-(benzenesulfonyl)propoxy]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=CC2=CN=C1NC(N=C1)=CC=C1OCCCS(=O)(=O)C1=CC=CC=C1 GLIAQJVFZZCNRM-UHFFFAOYSA-N 0.000 claims 1
- GDHUHDALUPEYNQ-UHFFFAOYSA-N 2-[[5-[bis(2-hydroxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCO)CCO)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 GDHUHDALUPEYNQ-UHFFFAOYSA-N 0.000 claims 1
- RNSUPAGDKUJPOH-UHFFFAOYSA-N 2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 RNSUPAGDKUJPOH-UHFFFAOYSA-N 0.000 claims 1
- FUPSONGCEPFMNO-UHFFFAOYSA-N 2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 FUPSONGCEPFMNO-UHFFFAOYSA-N 0.000 claims 1
- YDDZYJNEXVSNOR-UHFFFAOYSA-N 6-acetyl-2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC1=CC=C(NCCN)C=N1 YDDZYJNEXVSNOR-UHFFFAOYSA-N 0.000 claims 1
- QTZVWABNQLQVPQ-UHFFFAOYSA-N 6-acetyl-2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCC(N)C1 QTZVWABNQLQVPQ-UHFFFAOYSA-N 0.000 claims 1
- IQKCFVDADWUFCR-UHFFFAOYSA-N 6-acetyl-2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(C(C)(C)N)C1 IQKCFVDADWUFCR-UHFFFAOYSA-N 0.000 claims 1
- WNFVIHQULLTZRP-UHFFFAOYSA-N 6-acetyl-2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 WNFVIHQULLTZRP-UHFFFAOYSA-N 0.000 claims 1
- PNYDSWBFIYYAOD-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 PNYDSWBFIYYAOD-UHFFFAOYSA-N 0.000 claims 1
- NVURUIMJTOVZJR-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2,6-dimethylmorpholin-4-yl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)OC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 NVURUIMJTOVZJR-UHFFFAOYSA-N 0.000 claims 1
- JDAYPETZCPTRRN-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 JDAYPETZCPTRRN-UHFFFAOYSA-N 0.000 claims 1
- RSOGDQWTVSCHQY-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 RSOGDQWTVSCHQY-UHFFFAOYSA-N 0.000 claims 1
- YAWYHLNWDSFVDA-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 YAWYHLNWDSFVDA-UHFFFAOYSA-N 0.000 claims 1
- SUMIDHRKHFHCBN-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 SUMIDHRKHFHCBN-UHFFFAOYSA-N 0.000 claims 1
- OTNPSIGYUQFCTR-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(diethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CC)CC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 OTNPSIGYUQFCTR-UHFFFAOYSA-N 0.000 claims 1
- GYICIMVQXWJGLP-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 GYICIMVQXWJGLP-UHFFFAOYSA-N 0.000 claims 1
- VEQOPAOFGZKFHM-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-[2-(diethylamino)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 VEQOPAOFGZKFHM-UHFFFAOYSA-N 0.000 claims 1
- GGNIULHSXFVFEY-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 GGNIULHSXFVFEY-UHFFFAOYSA-N 0.000 claims 1
- MJMAOJBJOJYBLM-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 MJMAOJBJOJYBLM-UHFFFAOYSA-N 0.000 claims 1
- MZBKJNDTXYIZDF-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCCC1 MZBKJNDTXYIZDF-UHFFFAOYSA-N 0.000 claims 1
- CTQWHSWXTOSBOZ-UHFFFAOYSA-N 6-amino-2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 CTQWHSWXTOSBOZ-UHFFFAOYSA-N 0.000 claims 1
- WXQRJGNEEAQTOZ-UHFFFAOYSA-N 6-amino-2-[[5-(azetidin-1-yl)pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC1 WXQRJGNEEAQTOZ-UHFFFAOYSA-N 0.000 claims 1
- UOMYGSOEHPHNDW-UHFFFAOYSA-N 6-amino-2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C(C)(N)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(N)C(=O)N2C3CCCC3)C2=N1 UOMYGSOEHPHNDW-UHFFFAOYSA-N 0.000 claims 1
- CCWNTMZZYJTKES-UHFFFAOYSA-N 6-amino-8-cyclopentyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1NCC1=CC=C(F)C=C1 CCWNTMZZYJTKES-UHFFFAOYSA-N 0.000 claims 1
- SIQIWCNODPCHCT-UHFFFAOYSA-N 6-benzyl-8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CNC(C)(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CC=2C=CC=CC=2)C(=O)N2C3CCCC3)C2=N1 SIQIWCNODPCHCT-UHFFFAOYSA-N 0.000 claims 1
- AFJKDJWTFSKEMJ-UHFFFAOYSA-N 6-benzyl-8-cyclopentyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CC=2C=CC=CC=2)C(=O)N2C3CCCC3)C2=N1 AFJKDJWTFSKEMJ-UHFFFAOYSA-N 0.000 claims 1
- YCMUTOLJHOBKHY-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 YCMUTOLJHOBKHY-UHFFFAOYSA-N 0.000 claims 1
- XTUCGPNYJALZMM-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 XTUCGPNYJALZMM-UHFFFAOYSA-N 0.000 claims 1
- RRVRSGAVDBJKMR-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCNCC1 RRVRSGAVDBJKMR-UHFFFAOYSA-N 0.000 claims 1
- WGOXOVKLYPJIKG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCC1 WGOXOVKLYPJIKG-UHFFFAOYSA-N 0.000 claims 1
- CNGPKXNERYPGSQ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 CNGPKXNERYPGSQ-UHFFFAOYSA-N 0.000 claims 1
- XSRCBEDXCLKGBI-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 XSRCBEDXCLKGBI-UHFFFAOYSA-N 0.000 claims 1
- RJGGLQRGMFWGTR-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 RJGGLQRGMFWGTR-UHFFFAOYSA-N 0.000 claims 1
- SGATYRVXUSFHRN-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 SGATYRVXUSFHRN-UHFFFAOYSA-N 0.000 claims 1
- KLTWTROREGKPHD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 KLTWTROREGKPHD-UHFFFAOYSA-N 0.000 claims 1
- KPISUGGNPLIEMU-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)sulfonylpyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 KPISUGGNPLIEMU-UHFFFAOYSA-N 0.000 claims 1
- DDSHJIKUJXNHKG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)sulfonylpyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 DDSHJIKUJXNHKG-UHFFFAOYSA-N 0.000 claims 1
- GQVWQJOTSJFCHL-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(diethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CC)CC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 GQVWQJOTSJFCHL-UHFFFAOYSA-N 0.000 claims 1
- RRKLALYYANVTSA-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 RRKLALYYANVTSA-UHFFFAOYSA-N 0.000 claims 1
- RBQVAXVVMTZLFT-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 RBQVAXVVMTZLFT-UHFFFAOYSA-N 0.000 claims 1
- CCCDCVCYTAQWHL-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1CNC(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 CCCDCVCYTAQWHL-UHFFFAOYSA-N 0.000 claims 1
- ZTLYXLBPZZWPHG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-[2-(diethylamino)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 ZTLYXLBPZZWPHG-UHFFFAOYSA-N 0.000 claims 1
- CHQDKNRHNGRBFW-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCOCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 CHQDKNRHNGRBFW-UHFFFAOYSA-N 0.000 claims 1
- GPSKAQVGRRENNK-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CCOCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 GPSKAQVGRRENNK-UHFFFAOYSA-N 0.000 claims 1
- DZCHDINWDGTTBZ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 DZCHDINWDGTTBZ-UHFFFAOYSA-N 0.000 claims 1
- ZJVMZDYQLYDXNY-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CCNCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 ZJVMZDYQLYDXNY-UHFFFAOYSA-N 0.000 claims 1
- CWYYESQEGIFPQG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(6-methyl-5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C=1C=C(N2CCNCC2)C(C)=NC=1NC(N=C12)=NC=C1C(C)=C(Br)C(=O)N2C1CCCC1 CWYYESQEGIFPQG-UHFFFAOYSA-N 0.000 claims 1
- SAFPZVKGPSYIMD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 SAFPZVKGPSYIMD-UHFFFAOYSA-N 0.000 claims 1
- IJKNQIIVZWJZOR-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CNC(C)(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 IJKNQIIVZWJZOR-UHFFFAOYSA-N 0.000 claims 1
- YBKVHGLXMPJGMW-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNC(C)(C)C1 YBKVHGLXMPJGMW-UHFFFAOYSA-N 0.000 claims 1
- UAQJRRMSPQQIKU-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 UAQJRRMSPQQIKU-UHFFFAOYSA-N 0.000 claims 1
- FBRLMVUKRZGECH-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CC(C)NC(C)C1 FBRLMVUKRZGECH-UHFFFAOYSA-N 0.000 claims 1
- HWZVQBCJZYUUCA-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-(3,5-dimethylpiperazin-1-yl)propyl-methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1CCCN(C)C(C=N1)=CC=C1NC1=NC=C(C=CC(=O)N2C3CCCC3)C2=N1 HWZVQBCJZYUUCA-UHFFFAOYSA-N 0.000 claims 1
- YTQUGTPCYPXVEQ-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-(ethylamino)pyrrolidin-1-yl]pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(NCC)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 YTQUGTPCYPXVEQ-UHFFFAOYSA-N 0.000 claims 1
- WCYQLEMBUSZVBY-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-imidazol-1-ylpropyl(methyl)amino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C=1C=C(NC=2N=C3N(C4CCCC4)C(=O)C=CC3=CN=2)N=CC=1N(C)CCCN1C=CN=C1 WCYQLEMBUSZVBY-UHFFFAOYSA-N 0.000 claims 1
- PMDLISZAAKTUHC-UHFFFAOYSA-N 8-cyclopentyl-6-(1-ethoxyethenyl)-5-methyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=C)OCC)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCN(C)CC1 PMDLISZAAKTUHC-UHFFFAOYSA-N 0.000 claims 1
- AFNOMJNGXFOVCJ-UHFFFAOYSA-N 8-cyclopentyl-6-(ethoxymethyl)-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(COCC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 AFNOMJNGXFOVCJ-UHFFFAOYSA-N 0.000 claims 1
- CYWHSKRZQLMHLA-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[(5-methylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(S(=O)(=O)C)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 CYWHSKRZQLMHLA-UHFFFAOYSA-N 0.000 claims 1
- CSRIIOZYVDOZIR-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CO)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCC1 CSRIIOZYVDOZIR-UHFFFAOYSA-N 0.000 claims 1
- OLEZGEUVISNETL-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 OLEZGEUVISNETL-UHFFFAOYSA-N 0.000 claims 1
- LUZIOVSCTPHSLJ-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[[5-(2-methoxyethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCOC)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 LUZIOVSCTPHSLJ-UHFFFAOYSA-N 0.000 claims 1
- OZYCABBZTCNNQB-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 OZYCABBZTCNNQB-UHFFFAOYSA-N 0.000 claims 1
- WIZPNVWJXAAYER-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCNCC1 WIZPNVWJXAAYER-UHFFFAOYSA-N 0.000 claims 1
- XQUSLYNLFSDUHT-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1NCC1=CC=C(F)C=C1 XQUSLYNLFSDUHT-UHFFFAOYSA-N 0.000 claims 1
- YZESSMTVDITIOO-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[[5-[2-(2-methoxyethoxy)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC1=CC=C(OCCOCCOC)C=N1 YZESSMTVDITIOO-UHFFFAOYSA-N 0.000 claims 1
- BWQCRPSZHRGYAS-UHFFFAOYSA-N 8-cyclopentyl-6-fluoro-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;hydrochloride Chemical compound Cl.N1=C2N(C3CCCC3)C(=O)C(F)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 BWQCRPSZHRGYAS-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 241000450599 DNA viruses Species 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002464 muscle smooth vascular Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 150000003930 2-aminopyridines Chemical class 0.000 abstract 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35087702P | 2002-01-22 | 2002-01-22 | |
| PCT/IB2003/000059 WO2003062236A1 (en) | 2002-01-22 | 2003-01-10 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MEP46108A MEP46108A (en) | 2011-02-10 |
| ME00230B true ME00230B (me) | 2011-02-10 |
Family
ID=27613435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-461A ME00230B (me) | 2002-01-22 | 2003-01-10 | 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni |
Country Status (52)
Families Citing this family (326)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| AU2001298008A1 (en) * | 2000-08-04 | 2003-04-07 | Warner-Lambert Company | Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido (2,3-d)pyrimidin-7-ones |
| CA2417937A1 (en) * | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| WO2002064594A2 (en) * | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| NZ527741A (en) | 2001-02-26 | 2005-02-25 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
| EP1408985A4 (en) * | 2001-06-21 | 2006-03-22 | Ariad Pharma Inc | NEW PYRIDOPYRIMIDONE AND ITS USES |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| PL220952B1 (pl) | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
| BR0313297A (pt) | 2002-08-06 | 2005-06-21 | Hoffmann La Roche | 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| RU2350617C2 (ru) | 2003-04-10 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр |
| ATE412650T1 (de) * | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| JP4681548B2 (ja) | 2003-07-22 | 2011-05-11 | アステックス・セラピューティクス・リミテッド | ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用 |
| BRPI0413059A (pt) * | 2003-07-29 | 2006-10-31 | Xenon Pharmaceuticals Inc | derivados de piridila e seu uso como agentes terapêuticos |
| EP1685131B1 (en) * | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス， インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
| WO2005080393A1 (en) * | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2555724A1 (en) * | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| EP1761528B1 (en) * | 2004-06-11 | 2008-01-09 | Japan Tobacco, Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| ES2552338T3 (es) * | 2005-01-21 | 2015-11-27 | Astex Therapeutics Limited | Compuestos farmacéuticos |
| RU2007131101A (ru) * | 2005-01-21 | 2009-02-27 | Астекс Терапьютикс Лимитед (Gb) | Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований |
| MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| EP1852432A4 (en) * | 2005-02-25 | 2010-04-14 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE |
| TW200724142A (en) * | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
| TWI389690B (zh) * | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物（一） |
| RS54876B1 (sr) | 2005-05-10 | 2016-10-31 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| KR100734837B1 (ko) * | 2005-09-16 | 2007-07-03 | 한국전자통신연구원 | 다중 생체 인식 시스템 및 그 방법 |
| WO2007036791A1 (en) * | 2005-09-28 | 2007-04-05 | Ranbaxy Laboratories Limited | Pyrido-pyridimidine derivatives useful as antiinflammatory agents |
| GEP20115304B (en) * | 2005-10-07 | 2011-10-10 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
| JP2009536186A (ja) * | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
| US8716327B2 (en) | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
| EP2069344A2 (en) * | 2006-09-08 | 2009-06-17 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| ES2366489T3 (es) | 2006-09-15 | 2011-10-20 | Pfizer Products Inc. | Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3. |
| CA2665384A1 (en) * | 2006-10-16 | 2008-04-24 | Gpc Biotech Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
| WO2008150260A1 (en) * | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| JP2010509265A (ja) * | 2006-11-09 | 2010-03-25 | エフ．ホフマン−ラ ロシュ アーゲー | キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2009045503A1 (en) | 2007-10-05 | 2009-04-09 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
| NZ586069A (en) | 2007-12-19 | 2012-05-25 | Amgen Inc | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| ATE531372T1 (de) | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| SMT201800206T1 (it) | 2008-07-08 | 2018-05-02 | Incyte Holdings Corp | 1,2,5-ossadiazoli come inibitori di indoleamina 2,3-diossigenasi |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| PE20110419A1 (es) * | 2008-08-22 | 2011-07-13 | Novartis Ag | Compuestos de pirrolo-pirimidina como inhibidores de cdk |
| CA2738909A1 (en) * | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| EP2341911A4 (en) * | 2008-10-01 | 2012-10-24 | Univ North Carolina | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6 |
| CA2738768C (en) * | 2008-10-03 | 2017-10-31 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| ES2561216T3 (es) * | 2009-05-13 | 2016-02-25 | The University Of North Carolina At Chapel Hill | Inhibidores de cinasas dependientes de ciclina y procedimientos de uso |
| JPWO2011025006A1 (ja) * | 2009-08-31 | 2013-01-31 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| CA2776770A1 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
| JP5797664B2 (ja) * | 2009-12-18 | 2015-10-21 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ | 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用 |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| JP5918214B2 (ja) * | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| WO2011156786A2 (en) * | 2010-06-10 | 2011-12-15 | Afraxis, Inc. | 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| US9376664B2 (en) | 2010-06-14 | 2016-06-28 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EA022527B1 (ru) | 2010-08-05 | 2016-01-29 | Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ |
| CN106967074A (zh) | 2010-10-25 | 2017-07-21 | G1治疗公司 | Cdk抑制剂 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| EP2640394A4 (en) | 2010-11-17 | 2015-02-25 | Univ North Carolina | PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| CN103517710B (zh) | 2011-02-07 | 2017-05-31 | 普莱希科公司 | 用于激酶调节的化合物 |
| ES2620521T3 (es) * | 2011-03-23 | 2017-06-28 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| JP2014522396A (ja) | 2011-05-27 | 2014-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 置換２−ベンジリデン−２Ｈ−ベンゾ［ｂ］［１，４］チアジン−３（４Ｈ）−オン、その誘導体及びその治療上の使用 |
| TR201811976T4 (tr) * | 2012-03-14 | 2018-09-21 | Lupin Ltd | Mek inhibitörleri olarak heterosiklil bileşikleri. |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| PL2872491T3 (pl) | 2012-07-11 | 2021-12-13 | Blueprint Medicines Corporation | Inhibitory receptora czynnika wzrostu fibroblastów |
| EP4119676A1 (en) | 2012-08-03 | 2023-01-18 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2885303B1 (en) | 2012-08-17 | 2018-12-26 | CoNCERT Pharmaceuticals, Inc. | Deuterated baricitinib |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| ES2694787T3 (es) | 2013-02-21 | 2018-12-27 | Pfizer Inc. | Formas sólidas de un inhibidor selectivo de CDK4/6 |
| WO2014144740A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| EA032094B1 (ru) | 2013-03-15 | 2019-04-30 | Консерт Фармасьютикалс, Инк. | Дейтерированный палбоциклиб |
| CN108434149B (zh) | 2013-03-15 | 2021-05-28 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
| ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
| CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| RU2704112C2 (ru) | 2013-10-25 | 2019-10-24 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| EP3082423B1 (en) * | 2013-12-20 | 2024-12-11 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| US9949976B2 (en) | 2013-12-31 | 2018-04-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| ES2687477T3 (es) | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Inhibidor de quinasa y su uso |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
| TWI675028B (zh) | 2014-07-24 | 2019-10-21 | 美商貝達醫藥公司 | 做為週期素依賴型激酶（ｃｄｋ）抑制劑之2-ｈ-吲唑衍生物及其醫療用途 |
| WO2016015598A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| EP3174878A4 (en) * | 2014-07-31 | 2017-12-27 | Sun Pharmaceutical Industries Limited | A process for the preparation of palbociclib |
| WO2016024232A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| US20170240543A1 (en) * | 2014-08-14 | 2017-08-24 | Sun Pharmaceutical Industries Limited | Crystalline forms of palbociclib |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016066420A1 (en) * | 2014-10-29 | 2016-05-06 | Sandoz Ag | Crystalline forms of palbociclib monohydrochloride |
| CN105622638B (zh) * | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
| CN105616418A (zh) * | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
| US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN104496983B (zh) * | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| WO2016090257A1 (en) * | 2014-12-05 | 2016-06-09 | Crystal Pharmatech Inc. | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) |
| WO2016092442A1 (en) * | 2014-12-08 | 2016-06-16 | Sun Pharmaceutical Industries Limited | Processes for the preparation of crystalline forms of palbociclib acetate |
| CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| JP6581197B2 (ja) | 2014-12-31 | 2019-09-25 | 深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． | 医薬組成物及びその製造方法 |
| CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
| CZ201589A3 (cs) | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| TWI690533B (zh) | 2015-02-12 | 2020-04-11 | 南北兄弟藥業投資有限公司 | Ｃｄｋ類小分子抑制劑的化合物及其用途 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
| EP3078663A1 (en) | 2015-04-09 | 2016-10-12 | Sandoz Ag | Modified particles of palbociclib |
| CN106795159B (zh) * | 2015-04-22 | 2018-12-28 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
| TWI696617B (zh) * | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| PT3305785T (pt) * | 2015-05-29 | 2021-10-13 | Teijin Pharma Ltd | Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável |
| HUE047477T2 (hu) | 2015-06-04 | 2020-04-28 | Pfizer | Palbociclib szilárd dózisformái |
| CN104892604B (zh) * | 2015-06-19 | 2016-08-24 | 北京康立生医药技术开发有限公司 | 一种cdk4抑制剂的合成方法 |
| CN106699785A (zh) * | 2015-07-13 | 2017-05-24 | 南开大学 | 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物 |
| WO2017021111A1 (en) * | 2015-08-05 | 2017-02-09 | Ratiopharm Gmbh | New crystalline form and acetic acid adducts of palbociclib |
| CN105085517B (zh) * | 2015-08-06 | 2016-11-23 | 天津华洛康生物科技有限公司 | 一种结晶型帕博西尼游离碱水合物及其制备方法 |
| CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| HU230962B1 (hu) | 2015-10-28 | 2019-06-28 | Egis Gyógyszergyár Zrt. | Palbociclib sók |
| CN106632311B (zh) * | 2015-11-02 | 2021-05-18 | 上海科胜药物研发有限公司 | 一种帕博西尼晶型a和晶型b的制备方法 |
| CN108463248B (zh) | 2015-11-12 | 2022-10-21 | 西雅图基因公司 | 聚糖相互作用化合物及使用方法 |
| CN105418603A (zh) * | 2015-11-17 | 2016-03-23 | 重庆莱美药业股份有限公司 | 一种高纯度帕布昔利布及其反应中间体的制备方法 |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| US11225492B2 (en) | 2015-12-13 | 2022-01-18 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| ES2994614T3 (en) | 2015-12-31 | 2025-01-27 | Shanghai Pharmaceuticals Holding Co Ltd | Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof |
| CN105418609B (zh) * | 2015-12-31 | 2017-06-23 | 山东大学 | 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用 |
| CN106967061A (zh) * | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
| WO2017130219A1 (en) | 2016-01-25 | 2017-08-03 | Mylan Laboratories Limited | Amorphous solid dispersion of palbociclib |
| WO2017145054A1 (en) | 2016-02-24 | 2017-08-31 | Lupin Limited | Modified particles of crystalline palbociclib free base and process for the preparation thereof |
| US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| CN107266421B (zh) * | 2016-04-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 取代的苯并咪唑类衍生物 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| WO2017185031A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| CN106336411B (zh) * | 2016-04-27 | 2018-03-06 | 上海医药集团股份有限公司 | Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途 |
| CN105949189B (zh) * | 2016-06-05 | 2017-09-22 | 童明琼 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
| US10807978B2 (en) | 2016-07-04 | 2020-10-20 | Dr. Reddy's Laboratories Limited | Process for preparation of palbociclib |
| JP6870082B2 (ja) | 2016-07-07 | 2021-05-12 | プランテックス・リミテッド | 二メシル酸パルボシクリブの固体形態 |
| MA45920B1 (fr) * | 2016-08-15 | 2021-08-31 | Pfizer | Inhibiteurs de pyridopyrimidinone cdk2/4/6 |
| RU2769251C2 (ru) | 2016-08-23 | 2022-03-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Комбинированная терапия для лечения гепатоцеллюлярной карциномы |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| WO2018065999A1 (en) | 2016-10-07 | 2018-04-12 | Mylan Laboratories Limited | Novel polymorph of an intermediate for palbociclib synthesis |
| ES2934846T3 (es) | 2016-10-20 | 2023-02-27 | Pfizer | Inhibidores de CDK para tratamiento de PAH |
| WO2018073574A1 (en) | 2016-10-20 | 2018-04-26 | Cipla Limited | Polymorphic forms of palbociclib |
| CN106565707B (zh) * | 2016-11-03 | 2019-01-04 | 杭州科巢生物科技有限公司 | 帕博西尼新合成方法 |
| WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| WO2018091999A1 (en) | 2016-11-16 | 2018-05-24 | Pfizer Inc. | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CA3043561C (en) | 2016-11-28 | 2025-03-11 | Teijin Pharma Limited | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| PT3546456T (pt) | 2016-11-28 | 2022-02-28 | Teijin Pharma Ltd | Cristal de derivado da pirido[3,4-d]pirimidina ou seu solvato |
| IL267299B (en) | 2016-12-16 | 2022-09-01 | Cstone Pharmaceuticals | Cdk4/6 inhibitor |
| IL267795B2 (en) | 2017-01-06 | 2023-02-01 | G1 Therapeutics Inc | Combination therapy for the treatment of cancer |
| CN108191857B (zh) * | 2017-01-24 | 2020-10-23 | 晟科药业（江苏）有限公司 | 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 |
| US10729692B2 (en) * | 2017-02-26 | 2020-08-04 | Institute For Cancer Research | Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| CA3054939A1 (en) | 2017-03-03 | 2018-09-07 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
| WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| CN108658854A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种生物碱化合物及其制备方法和作为海洋防污剂的应用 |
| CN108658855A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种含氮双环化合物及其制备方法和用途 |
| US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2018232235A1 (en) | 2017-06-16 | 2018-12-20 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| EA201992768A1 (ru) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
| EA036060B1 (ru) * | 2017-07-17 | 2020-09-21 | Пфайзер Инк. | Пиридопиримидиноновые ингибиторы cdk2/4/6 |
| EA202090402A1 (ru) | 2017-07-28 | 2020-05-19 | Синтон Б.В. | Фармацевтическая композиция, содержащая пальбоциклиб |
| CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
| EP3676404B1 (en) | 2017-08-31 | 2025-09-03 | Novartis AG | Methods of selecting a treatment for breast cancer patients |
| CN107488175A (zh) * | 2017-09-04 | 2017-12-19 | 上海微巨实业有限公司 | 一种帕博西林关键中间体的制备方法 |
| US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| CA3085366A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
| CA3088381A1 (en) | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| CN108218861B (zh) * | 2018-02-05 | 2019-07-23 | 黑龙江中医药大学 | 一种预防和治疗糖尿病的药物及其制备方法 |
| US11759450B2 (en) | 2018-02-06 | 2023-09-19 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| JP2021514975A (ja) | 2018-02-27 | 2021-06-17 | ファイザー・インク | サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ |
| KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| US11911383B2 (en) | 2018-05-14 | 2024-02-27 | Pfizer Inc. | Oral solution formulation |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| EP3802529B1 (en) | 2018-05-24 | 2023-11-01 | Synthon B.V. | A process for making palbociclib |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| EP3826622A1 (en) | 2018-07-23 | 2021-06-02 | F. Hoffmann-La Roche AG | Methods of treating cancer with pi3k inhibitor, gdc-0077 |
| KR20210062626A (ko) | 2018-07-27 | 2021-05-31 | 캘리포니아 인스티튜트 오브 테크놀로지 | Cdk 억제제 및 이의 용도 |
| KR20210049847A (ko) | 2018-08-24 | 2021-05-06 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| EP3863618A1 (en) | 2018-10-08 | 2021-08-18 | F. Hoffmann-La Roche AG | Methods of treating cancer with pi3k alpha inhibitors and metformin |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| TW202035406A (zh) | 2018-12-07 | 2020-10-01 | 大陸商杭州英創醫藥科技有限公司 | 作為cdk-hdac雙通路抑制劑的雜環化合物 |
| SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
| US20230048132A1 (en) * | 2018-12-28 | 2023-02-16 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20230065740A1 (en) | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20220125777A1 (en) | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| CA3130210A1 (en) * | 2019-02-15 | 2020-08-20 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| JP2022533833A (ja) | 2019-05-24 | 2022-07-26 | ファイザー・インク | Ｃｄｋ阻害剤を使用した組合せ療法 |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| CN112010844B (zh) * | 2019-05-31 | 2023-07-25 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN112094272A (zh) | 2019-06-18 | 2020-12-18 | 北京睿熙生物科技有限公司 | Cdk激酶抑制剂 |
| WO2020253808A1 (zh) * | 2019-06-20 | 2020-12-24 | 江苏恒瑞医药股份有限公司 | 一种药物组合物以及其制备方法 |
| CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2022543062A (ja) | 2019-08-01 | 2022-10-07 | インサイト・コーポレイション | Ｉｄｏ阻害剤の投与レジメン |
| CR20220066A (es) | 2019-08-14 | 2022-11-28 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| BR112022003490A2 (pt) | 2019-08-26 | 2022-05-24 | Arvinas Operations Inc | Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
| JP7675711B2 (ja) | 2019-10-14 | 2025-05-13 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112759589B (zh) * | 2019-11-01 | 2022-04-08 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| JP2023504436A (ja) | 2019-12-03 | 2023-02-03 | ジェネンテック， インコーポレイテッド | 乳がんの治療のための併用療法 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CR20220285A (es) | 2019-12-04 | 2022-10-27 | Incyte Corp | Derivados de un inhibidor de fgfr |
| MX2022007487A (es) | 2019-12-16 | 2022-08-04 | Lunella Biotech Inc | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. |
| JP7657222B2 (ja) | 2019-12-16 | 2025-04-04 | ルネラ・バイオテック・インコーポレーテッド | 選択的ｃｄｋ４／６阻害剤のがん治療薬 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| WO2021183994A1 (en) * | 2020-03-13 | 2021-09-16 | Prosenestar Llc | Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors |
| EP4126244A4 (en) * | 2020-03-27 | 2024-03-27 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | COMBINATION OF ANTI-HER2 ANTIBODIES AND CDK INHIBITORS FOR TUMOR TREATMENT |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CN121270549A (zh) | 2020-04-16 | 2026-01-06 | 因赛特公司 | 稠合三环kras抑制剂 |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| EP4153597B1 (en) | 2020-05-19 | 2025-09-10 | Pharmacosmos Holding A/S | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| EP4157847A4 (en) * | 2020-05-28 | 2024-06-19 | University of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN113880809B (zh) | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| CN116113407A (zh) | 2020-07-15 | 2023-05-12 | 辉瑞公司 | 用于癌症治疗的kat6抑制剂方法及组合 |
| CA3189632A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Combination therapy |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| WO2022063119A1 (zh) * | 2020-09-24 | 2022-03-31 | 南京济群医药科技股份有限公司 | 一种羟乙磺酸哌柏西利的组合物及药物 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| WO2022091001A1 (en) | 2020-10-29 | 2022-05-05 | Pfizer Ireland Pharmaceuticals | Process for preparation of palbociclib |
| WO2022123419A1 (en) | 2020-12-08 | 2022-06-16 | Pfizer Inc. | Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib |
| CN112569361B (zh) * | 2020-12-30 | 2023-01-10 | 扬子江药业集团上海海尼药业有限公司 | 一种哌柏西利干混悬组合物及其制备方法 |
| WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| WO2022258023A1 (zh) * | 2021-06-09 | 2022-12-15 | 郑州同源康医药有限公司 | 用作cdk激酶抑制剂的化合物及其应用 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| IL309642A (en) | 2021-07-07 | 2024-02-01 | Incyte Corp | Tricyclic compounds as inhibitors of Kras |
| US20230114765A1 (en) | 2021-07-14 | 2023-04-13 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US20240376096A1 (en) | 2021-07-16 | 2024-11-14 | Dana-Farber Cancer Institute, Inc. | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
| KR20240040768A (ko) | 2021-07-26 | 2024-03-28 | 셀퀴티 인크. | 암의 치료에 사용하기 위한 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물 |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
| CN118119393A (zh) * | 2021-09-14 | 2024-05-31 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| EP4408536A1 (en) | 2021-10-01 | 2024-08-07 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| US20230226040A1 (en) | 2021-11-22 | 2023-07-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20240398832A1 (en) | 2021-12-10 | 2024-12-05 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
| CA3244187A1 (en) | 2021-12-22 | 2023-06-29 | Incyte Corporation | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION |
| WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
| WO2023116884A1 (en) | 2021-12-24 | 2023-06-29 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| CN114456180B (zh) * | 2022-02-18 | 2023-07-25 | 贵州大学 | 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用 |
| IL315457A (en) | 2022-03-07 | 2024-11-01 | Incyte Corp | Solid forms, salts and preparation processes of the Sidikii2 inhibitor |
| HU231594B1 (hu) * | 2022-05-10 | 2025-03-28 | Egis Gyógyszergyár Zrt. | Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény |
| WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
| EP4302832A1 (en) | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing glucono delta lactone |
| EP4302755B1 (en) | 2022-07-07 | 2025-08-20 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing an amino acid |
| WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
| CN117430597A (zh) * | 2022-07-14 | 2024-01-23 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| US20260027087A1 (en) | 2022-07-29 | 2026-01-29 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| TW202539669A (zh) | 2022-08-31 | 2025-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| TWI863667B (zh) | 2022-11-02 | 2024-11-21 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| JP2025539034A (ja) | 2022-11-11 | 2025-12-03 | アストラゼネカ・アクチエボラーグ | 癌の治療のための併用療法 |
| WO2024125581A2 (zh) * | 2022-12-16 | 2024-06-20 | 上海岸阔医药科技有限公司 | 化合物及其用途 |
| WO2024133726A1 (en) | 2022-12-22 | 2024-06-27 | Synthon B.V. | Pharmaceutical composition comprising palbociclib |
| WO2024132652A1 (en) | 2022-12-22 | 2024-06-27 | Synthon B.V. | Pharmaceutical composition comprising palbociclib |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024201334A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
| WO2024220532A1 (en) | 2023-04-18 | 2024-10-24 | Incyte Corporation | Pyrrolidine kras inhibitors |
| TW202446371A (zh) | 2023-04-18 | 2024-12-01 | 美商英塞特公司 | ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑 |
| KR20260006644A (ko) | 2023-05-05 | 2026-01-13 | 아스트라제네카 아베 | 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합 |
| WO2024235844A1 (en) | 2023-05-12 | 2024-11-21 | Institut National de la Santé et de la Recherche Médicale | Methods of preventing on-target genotoxicity induced by nucleases |
| WO2024254245A1 (en) | 2023-06-09 | 2024-12-12 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2025051337A1 (en) | 2023-09-06 | 2025-03-13 | Afyx Development A/S | Compositions and methods for treating and preventing oral cancer |
| WO2025096738A1 (en) | 2023-11-01 | 2025-05-08 | Incyte Corporation | Kras inhibitors |
| TW202532065A (zh) | 2023-12-04 | 2025-08-16 | 美商建南德克公司 | 治療乳癌之組合療法 |
| WO2025129002A1 (en) | 2023-12-13 | 2025-06-19 | Incyte Corporation | Bicyclooctane kras inhibitors |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959474A (en) | 1979-06-14 | 1990-09-25 | Burroughs Wellcome Co. | Dialkoxy pyridopyrimidine compounds |
| JPS5618982A (en) | 1979-06-14 | 1981-02-23 | Wellcome Found | Pyrimidine derivatives and medicinal drug containing them |
| FI66866C (fi) | 1979-06-14 | 1984-12-10 | Wellcome Found | Foerfarande foer framstaellning av antiproliferativa 2,4-diamino-6-(dialkoxibensyl)pyrido(2,3-d)pyrimidiner |
| AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
| ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
| US5426110A (en) | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
| GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| RU2191188C2 (ru) | 1994-11-14 | 2002-10-20 | Варнер-Ламберт Компани | Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации |
| US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| JP2001511764A (ja) | 1996-04-12 | 2001-08-14 | 住友製薬株式会社 | ピペリジニルピリミジン誘導体 |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| ES2301194T3 (es) * | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| RO119463B1 (ro) | 1997-10-27 | 2004-11-30 | Agouron Pharmaceuticals, Inc. | Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk |
| EA003640B1 (ru) * | 1998-05-26 | 2003-08-28 | Варнер-Ламберт Компани | Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации |
| WO2000012485A1 (en) | 1998-08-29 | 2000-03-09 | Astrazeneca Ab | Pyrimidine compounds |
| CA2380389A1 (en) | 1999-07-26 | 2001-02-01 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| SK3542002A3 (en) | 1999-09-15 | 2003-04-01 | Warner Lambert Co | Pteridinones as kinase inhibitors |
| HUP0203803A3 (en) * | 2000-01-27 | 2004-09-28 | Warner Lambert Co | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| OA12227A (en) * | 2000-03-06 | 2004-03-18 | Warner Lambert Co | 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors. |
| CA2417942C (en) * | 2000-08-04 | 2010-06-29 | Warner-Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| ES2230337T3 (es) | 2000-09-01 | 2005-05-01 | Glaxo Group Limited | Derivados de oxindol. |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| WO2002064594A2 (en) * | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| ATE323706T1 (de) | 2001-12-17 | 2006-05-15 | Smithkline Beecham Corp | Pyrazolopyridazinderivate |
| PL220952B1 (pl) | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
| US7189712B2 (en) | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
| CA2507256A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Thiazolidine compounds in the treatment of anemic conditions |
| US20050009849A1 (en) * | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| WO2004076414A2 (en) | 2003-02-27 | 2004-09-10 | Smithkline Beecham Corporation | Novel compounds |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| EP2069344A2 (en) | 2006-09-08 | 2009-06-17 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
-
2003
- 2003-01-10 PL PL391191A patent/PL220952B1/pl unknown
- 2003-01-10 SI SI200330164T patent/SI1470124T1/sl unknown
- 2003-01-10 ES ES03700058T patent/ES2251677T3/es not_active Expired - Lifetime
- 2003-01-10 GE GE5674A patent/GEP20063909B/en unknown
- 2003-01-10 PL PL372046A patent/PL218692B1/pl unknown
- 2003-01-10 WO PCT/IB2003/000059 patent/WO2003062236A1/en not_active Ceased
- 2003-01-10 HR HRP20040660AA patent/HRP20040660B1/hr not_active IP Right Cessation
- 2003-01-10 ME MEP-2008-461A patent/ME00230B/me unknown
- 2003-01-10 KR KR1020047011276A patent/KR100669578B1/ko not_active Expired - Lifetime
- 2003-01-10 RS YUP-598/04A patent/RS51044B/sr unknown
- 2003-01-10 CN CN2011101150746A patent/CN102295643B/zh not_active Expired - Lifetime
- 2003-01-10 IL IL16272103A patent/IL162721A0/xx unknown
- 2003-01-10 CA CA2473026A patent/CA2473026C/en not_active Expired - Lifetime
- 2003-01-10 CN CN038025566A patent/CN101001857B/zh not_active Expired - Lifetime
- 2003-01-10 BR BR122016021801A patent/BR122016021801B8/pt not_active IP Right Cessation
- 2003-01-10 BR BRPI0307057A patent/BRPI0307057B8/pt active IP Right Grant
- 2003-01-10 AU AU2003237009A patent/AU2003237009B2/en active Active
- 2003-01-10 DK DK03700058T patent/DK1470124T3/da active
- 2003-01-10 KR KR1020067018532A patent/KR20060111716A/ko not_active Withdrawn
- 2003-01-10 EP EP03700058A patent/EP1470124B1/en not_active Expired - Lifetime
- 2003-01-10 EA EA200400860A patent/EA007395B3/ru active Protection Beyond IP Right Term
- 2003-01-10 CN CN2010102557666A patent/CN101906104B/zh not_active Expired - Lifetime
- 2003-01-10 DE DE60303009T patent/DE60303009T2/de not_active Expired - Lifetime
- 2003-01-10 OA OA1200400189A patent/OA12755A/en unknown
- 2003-01-10 MX MXPA04005939A patent/MXPA04005939A/es active IP Right Grant
- 2003-01-10 JP JP2003562114A patent/JP4291696B2/ja not_active Expired - Lifetime
- 2003-01-10 AT AT03700058T patent/ATE314370T1/de active
- 2003-01-10 AP APAP/P/2004/003085A patent/AP1767A/en active
- 2003-01-10 NZ NZ534069A patent/NZ534069A/en not_active IP Right Cessation
- 2003-01-14 DO DO2003000561A patent/DOP2003000561A/es unknown
- 2003-01-14 NI NI200300008A patent/NI200300008A/es unknown
- 2003-01-16 US US10/345,778 patent/US6936612B2/en not_active Expired - Lifetime
- 2003-01-16 PE PE2003000050A patent/PE20030975A1/es active IP Right Grant
- 2003-01-17 GT GT200300005A patent/GT200300005A/es unknown
- 2003-01-20 AR ARP030100158A patent/AR038814A1/es active IP Right Grant
- 2003-01-20 MY MYPI20030182A patent/MY134818A/en unknown
- 2003-01-21 TW TW092101242A patent/TWI343920B/zh active
- 2003-01-21 HN HN2003000039A patent/HN2003000039A/es unknown
- 2003-01-21 SV SV2003001459A patent/SV2004001459A/es not_active Application Discontinuation
- 2003-01-21 UY UY27617A patent/UY27617A1/es not_active Application Discontinuation
- 2003-01-22 PA PA20038563701A patent/PA8563701A1/es unknown
- 2003-10-01 UA UA20040706104A patent/UA79444C2/uk unknown
-
2004
- 2004-06-16 IS IS7323A patent/IS2423B/is unknown
- 2004-06-18 ZA ZA2004/04840A patent/ZA200404840B/en unknown
- 2004-06-24 IL IL162721A patent/IL162721A/en active Protection Beyond IP Right Term
- 2004-07-07 TN TNP2004000126A patent/TNSN04126A1/fr unknown
- 2004-07-15 MA MA27785A patent/MA27166A1/fr unknown
- 2004-07-22 EC EC2004005201A patent/ECSP045201A/es unknown
- 2004-07-22 CO CO04069500A patent/CO5700765A2/es not_active Application Discontinuation
- 2004-08-20 NO NO20043484A patent/NO329350B1/no not_active IP Right Cessation
-
2005
- 2005-01-28 US US11/046,126 patent/US7208489B2/en not_active Ceased
-
2006
- 2006-03-08 CY CY20061100324T patent/CY1105686T1/el unknown
-
2007
- 2007-04-11 US US11/734,200 patent/US7456168B2/en not_active Expired - Lifetime
-
2009
- 2009-04-20 IL IL198243A patent/IL198243A/en active IP Right Grant
-
2010
- 2010-01-05 EC EC2010005201A patent/ECSP105201A/es unknown
-
2011
- 2011-11-02 AR ARP110104062A patent/AR083686A2/es active IP Right Grant
-
2012
- 2012-03-19 CR CR20120129A patent/CR20120129A/es unknown
-
2017
- 2017-03-01 HU HUS1700009C patent/HUS1700009I1/hu unknown
- 2017-03-01 NL NL300863C patent/NL300863I2/nl unknown
- 2017-03-15 LU LU00009C patent/LUC00009I2/en unknown
- 2017-03-16 BE BE2017C005C patent/BE2017C005I2/fr unknown
- 2017-03-17 CY CY2017011C patent/CY2017011I2/el unknown
- 2017-04-19 NO NO2017014C patent/NO2017014I1/no unknown
- 2017-04-19 FR FR17C1012C patent/FR17C1012I2/fr active Active
- 2017-04-28 LT LTPA2017013C patent/LTC1470124I2/lt unknown
- 2017-05-04 HU HUS1700019C patent/HUS1700019I1/hu unknown
-
2018
- 2018-07-27 US US16/048,143 patent/USRE47739E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00230B (me) | 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni | |
| JP7579402B2 (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物 | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| CA2576269C (en) | Combinations for the treatment of diseases involving cell proliferation | |
| IL303451A (en) | PRMTS inhibitors | |
| CN114732910B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| JP2008528468A5 (show.php) | ||
| CA3034705A1 (en) | Inhibitors of cellular metabolic processes | |
| JP2019163290A (ja) | 新規グルタミナーゼ阻害剤 | |
| ES2652514T3 (es) | Compuestos heteroaromáticos como ligandos de dopamina D1 | |
| CA2778686C (en) | N-9-substituted purine compounds, compositions and methods of use | |
| JP2012511588A5 (show.php) | ||
| PH12012501386A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| CA2817460A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| SG146694A1 (en) | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo-2,3-c pyridin-2- ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | |
| CA2782213A1 (en) | 1,7-diazacarbazoles and their use in the treatment of cancer | |
| JP7603740B2 (ja) | シクロオレフィン置換複素芳香族化合物およびそれらの使用 | |
| HRP20250969T1 (hr) | Triciklički parp1 inhibitori i njihove uporabe | |
| JP2013511526A5 (show.php) | ||
| CN104447765A (zh) | 三环化合物及其药物组合物和应用 | |
| JP6250062B2 (ja) | がん、ウイルス感染症、及び肺疾患の処置のためのインドールの新規誘導体 | |
| JP2024516429A (ja) | メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用 | |
| RU2012138162A (ru) | Производные пиридазина для использования в качестве агонистов каннабинода-2 | |
| RU2020120538A (ru) | Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 | |
| RU2006138864A (ru) | Ингибиторы митотического кинезина |